GALNT1: A Potential Drug Target and Biomarker for GalNAc Transferase 1-mediated Diseases

Target Name: GALNT1

NCBI ID: G2589

GALNT1

Other Name(s): GalNAc transferase 1 | polypeptide GalNAc transferase 1 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) | GALNAC-T1 | GALNT1 variant 1 | GALT1_HUMAN | Polypeptide N-acetylgalactosaminyltransferase 1 soluble form | polypeptide N-acetylgalactosaminyltransferase 1 | pp-GaNTase 1 | Polypeptide N-acetylgalactosaminyltransferase 1 | Polypeptide GalNAc transferase 1 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 | UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1 | Protein-UDP acetylgalactosaminyltransferase 1 | GalNAc-T1 | Polypeptide N-acetylgalactosaminyltransferase 1, transcript variant 1 | protein-UDP acetylgalactosaminyltransferase 1

GALNT1: A Potential Drug Target and Biomarker for GalNAc Transferase 1-mediated Diseases

GALNT1 (GalNAc transferase 1) is a gene that encodes a enzyme involved in the transfer of the glucose group (GalNAc) from the donors to the acceptors in a type of sugar transport system called the transferase complex. The transferase complex is a key enzyme in the process of glucose uptake and utilization in various organisms, including humans. GALNT1 plays a crucial role in this process and is involved in the efficient transfer of GalNAc from the high-energy glucose-6-phosphate (glucose-6-phosphate) to the lower -energy glucose-6-phosphate.

GALNT1 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The potential targets of GALNT1 include cancer cells, neuroblastoma cells, and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

One of the main reasons for the potential targets of GALNT1 is its involvement in the transferase complex. The transferase complex is a key enzyme in the process of glucose uptake and utilization, and is involved in the efficient transfer of GalNAc from the high-energy glucose -6-phosphate to the lower-energy glucose-6-phosphate. Therefore, any disease that is characterized by impaired glucose uptake and utilization could be potential targets for GALNT1.

GALNT1 has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, GALNT1 has been shown to be involved in the development and progression of neuroblastoma, a type of cancer that affects the cells of the nervous system. Additionally, GALNT1 has been shown to be involved in the development and progression of Alzheimer's disease, a neurodegenerative disease that affects the memory and cognitive function.

Another potential target of GALNT1 is its involvement in the regulation of glucose metabolism. GALNT1 is involved in the transferase complex, which is responsible for the efficient transfer of GalNAc from the high-energy glucose-6-phosphate to the lower-energy glucose-6 -phosphate. Therefore, any disease that is characterized by impaired glucose metabolism could be potential targets for GALNT1.

GALNT1 has also been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. GALNT1 has also been shown to be involved in the regulation of cell adhesion by interacting with the protein E-cadherin, which is a transmembrane protein that is involved in cell-cell adhesion. Additionally, GALNT1 has been shown to be involved in the regulation of cell migration and invasion by interacting with the protein T-cell factor-4 (TNF-4), which is a cytokine that plays a role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

In conclusion, GALNT1 is a gene that encodes an enzyme involved in the transfer of the glucose group from the donors to the acceptors in a type of sugar transport system called the transferase complex. GALNT1 plays a crucial role in the efficient transfer of GalNAc from the high-energy glucose-6-phosphate to the lower-energy glucose-6-phosphate. Therefore, GALNT1 is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 1

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor (PubMed:8690719, PubMed:9295285). Has a broad spectrum of substrates such as apomucin-, MUC5AC-, MUC1- and MUC2-derived peptides (PubMed:9295285)

The "GALNT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets